ISSN |
1948-5182 (online) |
Open Access |
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ |
Copyright |
© The Author(s) 2016. Published by Baishideng Publishing Group Inc. All rights reserved.
|
Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
Website |
http://www.wjgnet.com |
Category |
Gastroenterology & Hepatology |
Manuscript Type |
Retrospective Study |
Article Title |
On-treatment quantitative hepatitis B e antigen predicted response to nucleos(t)ide analogues in chronic hepatitis B
|
Manuscript Source |
Invited Manuscript |
All Author List |
Yu-Hua Gao, Qing-Hua Meng, Zhan-Qing Zhang, Ping Zhao, Qing-Hua Shang, Quan Yuan, Yao Li, Juan Deng, Tong Li, Xue-En Liu and Hui Zhuang |
Funding Agency and Grant Number |
Funding Agency |
Grant Number |
Major Science and Technology Special Project of China Twelfth Five-year Plan |
2013ZX10002004 |
Major Science and Technology Special Project of China Twelfth Five-year Plan |
2012ZX10002003 |
|
Corresponding Author |
Xue-En Liu, MD, Associate Professor, Department of Microbiology and Infectious Disease Center, School of Basic Medical Sciences, Peking University Health Science Center, 38 Xueyuan Road, Haidian District, Beijing 100191, China. xueenliu@bjmu.edu.cn |
Key Words |
Response predictor; Quantitative detection; Hepatitis B e antigen; Hepatitis B virus DNA; Chronic hepatitis B; Nucleos(t)ide analogues |
Core Tip |
Few studies have systematically evaluated quantitative hepatitis B surface antigen, hepatitis B e antigen (HBeAg), hepatitis B core antibody, hepatitis B virus DNA and alanine aminotransferase for predicting treatment response to nucleos(t)ide analogues (NAs) in HBeAg-positive chronic hepatitis B (CHB). In this study, on-treatment HBeAg level as well as its declined value at 24-wk were identified to be the best predictors not only for 96-wk virological response (VR) but also for HBeAg seroconversion (SC). The combination of HBeAg level and its decline at 24-wk strongly predicted 96-wk VR and HBeAg SC with the AUROC of 0.923 and 0.928, respectively. Thus monitoring an early on-treatment HBeAg level and its decline may help to optimize NAs therapy for CHB patients. |
Publish Date |
2016-12-06 08:34 |
Citation |
Gao YH, Meng QH, Zhang ZQ, Zhao P, Shang QH, Yuan Q, Li Y, Deng J, Li T, Liu XE, Zhuang H. On-treatment quantitative hepatitis B e antigen predicted response to nucleos(t)ide analogues in chronic hepatitis B. World J Hepatol 2016; 8(34): 1511-1520 |
URL |
http://www.wjgnet.com/1948-5182/full/v8/i34/1511.htm |
DOI |
http://dx.doi.org/10.4254/wjh.v8.i34.1511 |